21 Questions to Ask a Supplement Manufacturer Before Wiring a Deposit

Which certifications should you verify rather than just ask about?

Verify GMP certification, NSF or USP marks, and FDA registration status against public records instead of taking a sales rep's word for it. FDA registration under 21 CFR 1.225 is an administrative listing, not a quality judgment. FDA's own consumer guidance states plainly that 'the agency does not approve manufacturing facilities independently,' and that mere registration 'does not denote approval of the establishment.' Under DSHEA, FDA also does not test dietary supplements before they reach market. A manufacturer who describes itself as 'FDA approved' has already told you something important about how carefully it reads its own rules.

Three certification programs cover most supplement niches, and each audits a different point in the chain. Match the mark to your actual product claims before paying for it, because they are not interchangeable.

None of the three publishes a flat certification fee, so budget for a quote rather than a number you saw on a forum. For the audit scope behind each badge and what it actually certifies, see FDA-Registered vs GMP-Certified vs NSF: Decoding Manufacturer Badges.

What testing questions separate real GMP shops from brokers?

Ask which specific test runs on every incoming lot and every finished batch, then ask to see it for your lot number specifically. 21 CFR 111.75(a)(1)(i) requires at least one identity test on 100% of incoming dietary-ingredient components, with no volume exemption absent an FDA-granted petition, and 111.75(c) separately requires finished-batch verification of identity, purity, strength and composition. A shop reselling someone else's production run can rarely produce lot-specific records on demand, because the records were never theirs to begin with.

A standard contaminant panel covers four heavy metals — arsenic, cadmium, lead and mercury — typically by ICP-MS, run alongside a microbiological panel covering aerobic plate count, yeast and mold, E. coli, Salmonella and staph. Ask for the actual document tied to your production lot, not a template the manufacturer reuses across customers. The difference between the two is exactly what a supplement certificate of analysis is supposed to prove.

Testing cost is a reasonable line to ask about too, since it varies by an order of magnitude depending on scope. Medallion Labs' published test catalog lists $164 per sample for a bundled four-metal heavy-metals package versus $334 ordered a-la-carte, and potency assay runs per analyte, at $80 for vitamin C against $300 for vitamin D. A six-ingredient formula multiplies that per-SKU cost by every label claim you're making.

How do you confirm you're talking to a factory and not a middleman?

Ask for the FDA facility registration number, then ask whether they own the equipment running your specific SKU. A broker can usually produce the first answer and rarely the second. Real factories quote MOQ by format because their equipment forces it: SMP Nutra's published FAQ lists 2,500-5,000 bottles per SKU for stock private label and 150,000-300,000 pieces for custom capsule or tablet formulas, figures a reseller has no reason to know off the top of their head. A vague 'it depends' to a specific format question is itself an answer.

Lead-time specificity works the same way. SMP Nutra quotes 8-10 weeks for new customers and 6-8 weeks for reorders once labels are on file, against a published industry range of roughly 4-8 weeks for private label and 8-16 weeks for custom formulations. A factory tends to land inside a tight, format-specific window, while a broker defaults to the wide industry range because it hasn't actually scheduled your run.

Before you commit to a full production run, request a small trial batch and watch how specifically they answer scheduling and packaging questions for it. What to ask for, what a legitimate sample run costs, and what red flags show up during one are covered in How to Sample a Supplement Manufacturer Before Ordering 5,000 Units.

What payment and deposit terms are normal?

No manufacturer publishes a standard deposit percentage, and the figure genuinely varies deal to deal — that specific number needs checking directly with each vendor rather than assumed from an industry norm. What you can pin down are the one-time setup costs layered on top of your per-unit price: published figures put formulation development at $2,000-$15,000, stability testing at $3,000-$8,000, tooling and custom molds at $5,000-$20,000, and label design at $500-$2,000, together adding roughly 20-40% on top of the quoted unit price. For a fuller breakdown of what that quoted price should include, see What a Supplement Bottle Actually Costs From the Manufacturer in 2026.

Setup fees aren't universal, either. Superior Supplement Manufacturing's published FAQ states it charges no setup fees for any of its services, including custom formulation development, which tells you a $0-fee quote isn't automatically a scam. It's one vendor's policy, not an industry floor. Ask which line items in your deposit correspond to which of these one-time costs, and get each one itemized separately.

COA testing typically runs $500-$2,000 per batch on top of everything else, so ask whether that cost sits inside your deposit or gets billed separately at delivery. A manufacturer who can't itemize deposit against setup, tooling and testing costs individually is either bundling to obscure margin, or hasn't actually priced your run yet.

Who owns the formula if you customize a stock product?

Most first-time buyers assume that paying for a custom tweak to a stock formula means they own the result. That assumption is usually wrong, and it may be the single costliest misunderstanding in this business. Formula ownership rides on contract language, not on what you call the relationship: under true contract manufacturing you own the formula and IP only if the development agreement explicitly says so, under private label the manufacturer owns the formula by default and you cannot move it to another factory, and under co-packing you keep the IP. Read the agreement for an assignment clause before you fund development, not after.

Customization also resets your minimum order quantity, sometimes drastically. SMP Nutra's own numbers show a stock gummy run starting as low as 1,000 bottles versus 500,000-1,000,000 pieces — 8,333-16,666 bottles at 60-count — for a custom gummy formula. That's roughly a tenfold jump in volume before you've validated the product sells.

If formula ownership matters to your exit plan or your ability to re-source later, put it in writing as its own clause, separate from the master service agreement. A verbal assurance that 'it's your formula' means nothing against a contract that's silent on assignment.

Which liability and insurance questions protect you if a batch fails?

Ask for a current certificate of product liability insurance naming your brand, and ask in writing who eats the cost of a batch that fails COA after it ships. Regulation gives you no backstop here, since FDA does not test or approve dietary supplements before they reach market. The liability firewall is entirely contractual and insurance-based, not regulatory, which means the manufacturer's paperwork is the only thing standing between a bad batch and your balance sheet.

Ask to see the structure of a batch production record, not the record itself. cGMP under 21 CFR Part 111 requires a master manufacturing record specifying exact component weights and theoretical yield, a batch record capturing lot number and the initials of two people who independently verified each addition, and quality-control personnel whose duties are kept separate from production. Records must be retained 1 year past the shelf-life date, or 2 years past last-batch distribution if no date is used.

Allergen handling belongs on this list too. US law recognizes nine major allergens, and FALCPA requires them declared either as 'Contains' language after the ingredient list or named in parentheses within it. Ask how the facility prevents cross-contact on shared equipment — a mislabeled allergen triggers a recall and a liability claim, not a labeling nitpick.

Which answers should end the conversation immediately?

Some answers aren't yellow flags, they're the end of the call. If you hear any of these, stop negotiating and go find another manufacturer.

• "We don't test every incoming lot" — 21 CFR 111.75(a)(1)(i) requires identity testing on 100% of dietary-ingredient lots, with no exemption absent an FDA-granted petition.
• "We'll send the COA after the run ships" — a COA you can't see before accepting production isn't a quality check, it's a formality.
• "We're FDA approved" — FDA does not approve manufacturing facilities or dietary supplements, and anyone who says this misunderstands their own regulatory status.
• "MOQ depends" in response to a direct, format-specific question — real factories know their equipment's minimums down to the bottle.
• A refusal to put deposit amount, lead time and formula-ownership language in writing before you pay anything.
• "ISO 17025 covers that" as an answer to a product-safety question — the accreditation certifies the lab's methods and scope, never the product itself.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For educational pages, the supporting references should help readers verify search, crawlability, and public ad research context, especially Google helpful content guidance, Google SEO link best practices, and Meta Ad Library. Daily Intel then adds the direct-response interpretation layer so the page explains what the signal means for actual affiliate research decisions.

For deeper evaluation, continue through Daily Intel research methodology, Value Optimization for Supplement Offers With Upsells and Rebills, Pausing Overnight, Weekends, and Between Tests: What It Costs, The Bottle Selector: Which Tier You Highlight and What It Costs You, The First Screen: What a Supplement Product Page Must Show Instantly, and What is a VSL?. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.